This paper is important as the most recent and perhaps most definitive failure in a series of randomized studies attempting to combine novel targeted agents with chemotherapy. It will be critical for investigators studying epidermal growth factor receptor (EGFR) pathways to understand why this 755-patient phase III clinical trial has failed. This study added cetuximab to combination chemotherapy in metastatic colorectal cancer....